Will PICCOLO affect metastatic colorectal cancer therapy?
Mené sur 1 198 patients atteints d'un cancer colorectal de stade avancé sans mutation du gène KRAS et ayant progressé après un traitement à l'aide de fluoropyrimidine, avec ou sans oxaliplatine, cet essai britannique évalue, du point de vue de la survie globale, l'ajout du panitumumab à l'irinotecan
Investigators, practitioners, and caregivers continue to seek treatment options to improve the overall survival of patients with unresectable metastatic colorectal cancer, only about 13% of whom are likely to be alive for more than 5 years after diagnosis. Panitumumab, a fully human anti-EGFR monoclonal antibody, is approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of patients with KRAS wild-type metastatic colorectal cancer as a single agent...
The Lancet Oncology , commentaire, 2012